CALA News and Press, Calithera Biosciences Inc. From 11/18/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com Earnings reports, IPOs, acquisition...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will p...

Image source: The Motley Fool. Calithera Biosciences, Inc (NASDAQ: CALA) Q3 2021 Earnings Call Nov 9, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Calithera Biosciences, Inc (CALA) Q3 2021 Earnings Call Transcrip...

Calithera Biosciences, Inc. (CALA) Q3 2021 Earnings Conference Call November 09, 2021 05:00 PM ET Company Participants Stephanie Wong - Chief Financial Officer Susan Molineaux - Founder, President & Chief Executive Officer Emil Kuriakose - Chief Medical Officer Conference Call Participant...

-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash equivalents and investments totaled $84.5 million as of September 30, 2021 -- -- Conferen...

Calithera Biosciences (NASDAQ:CALA) announces its decision to terminate the company's phase 2 KEAPSAKE trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. Shares drop more than 33% premarket. The phase 2 study was designe...

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the promotion of current vice president and head of clinical development, Dr. Emil T. Kuriakose, to chie...

--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired targeted oncology compounds sapanisertib and mivavotinib, as well as the ongoing trial of CB-280 for the treatment of cyst...

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s third quarter 2021 financial results will be released on Tuesday, Novembe...

Calithera Biosciences (NASDAQ:CALA) has added ~4.7% in the pre-market after the company reported interim Phase 1b data from a dose-escalation trial designed to evaluate CB-280 in adults with cystic fibrosis (CF). Data were generated from the first 24 subjects (18 treated with C...